Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- PFSB Notification Calls for Revisions of Precautions for Gabapentin, Other Drugs
March 28, 2013
- MHLW to Request Development of 2 Unapproved Indications Determined to Have Unmet Medical Needs
March 27, 2013
- PAFSC Committee Approves Reclassification of Tiquizium Bromide and Diclofenac as Class 2 OTC Drugs
March 26, 2013
- Administrative Evaluation: Health Ministry Urged to Review All-Specification Listing Requirement for Generics
March 25, 2013
- LDP Subcommittee Begins Discussions on Amending PAL; Bill Expected to Be Submitted During Current Diet Session
March 25, 2013
- Regulatory Reform Council Not Convinced of MHLW’s Response to Online Sale of OTC Drugs
March 25, 2013
- CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together
March 22, 2013
- PMDA’s FY2013 Project Plan OK’d; Discussions for 3rd Mid-Term Plan to Get Underway
March 21, 2013
- Government’s New Office to Compile Health and Medical Strategy by June, Appoints JPMA Teshirogi as Advisor
March 21, 2013
- PMDA Testing New System that Uses Electronic Medical Information to Help Assess Post-Marketing Drug Risk
March 21, 2013
- MHLW Announces 4-Year Extension of Reexamination Period for Adoair
March 21, 2013
- MHLW Issues Notification on Revised GVP, GPSP Ordinances
March 19, 2013
- LDP to Begin Discussions on Bill to Amend PAL; MHLW Aims to Submit Bill during Current Diet Session
March 19, 2013
- Payer Representative Tsuyoshi Kobayashi Questions Automatic Health Insurance Coverage for Additional Indications
March 15, 2013
- Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
- PAFSC’s Second Committee Recommends Approval for Pfizer’s JAK Inhibitor Xeljanz, Others
March 14, 2013
- LDP Policy Subcommittee Demands Ban on Mixed Healthcare in TPP Talks
March 13, 2013
- MHLW Panel Gives Nod to Electronic Prescribing
March 13, 2013
- MHLW Panel Gives Nod to Electronic Prescribing
March 13, 2013
- MHLW Reports 1st Death Following Quadruple Vaccine Immunization, Causality is Under Investigation
March 13, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…